Introduction to Lung Cancer

Lung cancer is the second most common malignancy in both men and women. In total, 90% of lung cancer–related fatalities are caused by smoking, which is a key risk factor for the disease. Small-cell carcinomas and non-small-cell carcinomas are the two types of lung cancer that may be generically categorised. Up to 75% of lung cancer cases are non-small-cell lung cancer (NSCLC), which is more prevalent. Chest radiography, sputum cytology, bronchoscopy, needle biopsy, and other procedures are used to diagnose lung cancer. Stage I and stage II, NSCLC are all managed largely by surgery; however, stage III illness may also be treated this way. Surgery may be an option for patients with stage IIIa disease, although the likelihood of survival is decreased if mediastinal lymph nodes are involved. Adjuvant irradiation does not prolong survival time, but it may lower the incidence of local recurrence. When combined with cisplatin, adjuvant treatment may offer a little survival-time benefit. Radiation treatment alone may not be as effective in improving survival as chemotherapy coupled with it. Advanced NSCLC patients should get treatment in combination. Over the finest supportive care, a number of regimens have demonstrated a survival benefit. Along with surgery and radiation therapy, chemotherapy is becoming a more significant component in the treatment of this illness. A newer form of treatment called immunotherapy employs monoclonal antibodies to target several pathways involved in the growth of cancer. Both individually and in combination, paclitaxel, docetaxel, gemcitabine, vinorelbine, irinotecan, and topotecan are active. Surgery is only sometimes used to treat small-cell lung cancer (SCLC). Patients with mild illness should get radiation treatment in addition to a platinum-based chemotherapy regimen. Patients with advanced illness should be provided combination chemotherapy. The categorisation, aetiology, pathophysiology, clinical characteristics, diagnostic techniques, and therapy options for lung cancer are all briefly discussed in this chapter.